AI Article Synopsis
- Inflamm-aging is linked to various age-related diseases, and this study investigates the safety and effectiveness of using autologous mesenchymal stem cells (AD-MSCs) in patients with low-grade inflammation related to aging.
- The trial involved 12 patients receiving two infusions of 100 million AD-MSCs, and the effects were monitored by measuring plasma cytokine levels.
- Results showed that after 180 days, participants experienced a significant reduction in harmful inflammatory cytokines, indicating that AD-MSCs could help mitigate age-related inflammation.
Article Abstract
Background: Inflamm-aging is associated with the rate of aging and is significantly related to diseases such as Alzheimer's disease, Parkinson's disease, atherosclerosis, heart disease, and age-related degenerative diseases such as type II diabetes and osteoporosis. This study aims to evaluate the safety and efficiency of autologous adipose tissue-derived mesenchymal stem cell (AD-MSC) transplantation in aging-related low-grade inflammation patients.
Methods: This study is a single-group, open-label, phase I clinical trial in which patients treated with 2 infusions (100 million cells i.v) of autologous AD-MSCs were initially evaluated in 12 inflamm-aging patients who concurrently had highly proinflammatory cytokines and 2 of the following 3 diseases: diabetes, dyslipidemia, and obesity. The treatment effects were evaluated based on plasma cytokines.
Results: During the study's follow-up period, no adverse effects were observed in AD-MSC injection patients. Compared to baseline (D-44), the inflammatory cytokines IL-1α, IL-1β, IL-8, IL-6, and TNF-α were significantly reduced after 180 days (D180) of MSC infusion. IL-4/IL-10 at 90 days (D90) and IL-2/IL-10 at D180 increased, reversing the imbalance between proinflammatory and inflammatory ratios in the patients.
Conclusion: AD-MSCs represent a potential intervention to prevent age-related inflammation in patients.
Trial Registration: ClinicalTrials.gov number is NCT05827757, first registered on 13th Oct 2020.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11077870 | PMC |
| http://dx.doi.org/10.1186/s13063-024-08128-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autologous Fat Injection for Rhinoplasty: A Systematic Review of Satisfaction, Reinjection and Fat Retention.
Aesthetic Plast Surg
January 2025
Department of Plastic Surgery and Burns Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China.
Background: Autologous fat injection has been proposed as a potential alternative to traditional rhinoplasty. However, the technique has been criticized for its disappointing retention and the potential complications associated with underfilling.
Objective: To summarize data on patient satisfaction, retention, complications and reinjection to provide a reference for fat injection for rhinoplasty.
Hyaluronic acid-based dermal substitute with stromal vascular fraction vs. partial thickness skin grafts for the treatment of intermediate-deep burns of the hand: a retrospective case-control study.
Ann Burns Fire Disasters
December 2024
Division of Plastic and Reconstructive Surgery, Department of Precision and Regenerative Medicine and Jonic Area, University of Bari, Bari, Italy.
Deep intermediate burns of the hand are a challenge for both the functional and aesthetic result. In this study we compare the efficacy of early selective enzymatic escarolysis followed by the application of stromal vascular fraction (SVF) extracted from autologous adipose tissue on a dermal substitute scaffold (DS) versus reconstruction by partial thickness skin grafts (PTSG). We enrolled all patients admitted to our referral Burn Center from September 2020 to January 2022 with deep intermediate burns of the hands: clinical data were collected, then the first group of 4 patients were treated with PTSG surgical reconstruction, and the second group of 7 patients with DS+SVF.
View Article and Find Full Text PDFStem cell therapy approaches for non-malignant diseases & non-haematological diseases in India: A systematic review.
Indian J Med Res
November 2024
Department of Pediatrics, All India Institute of Medical Sciences, Patna, India.
Background & objectives Our study aims to provide the diversity of stem cell use for non-malignant, non-haematological diseases in India through the lens of clinical trials. Methods A PRISMA approach was used to evaluate the safety and efficacy of stem cell use for the period 2001-2021 in India. The outcomes were measured using each disease category, types of stem cells, the origin of stem cells, safety, and efficacy.
View Article and Find Full Text PDFEffectiveness and Safety of Micro-Plasma Radiofrequency Treatment Combined With Autologous Chyle Fat Grafting Treatment for Hypertrophic Scars: A Retrospective Study.
J Cosmet Dermatol
January 2025
Department of Plastic and Reconstructive Surgery, Senior Department of Burns and Plastic Surgery, The Fourth Medical Center of Chinese PLA General Hospital, Beijing, China.
Background: Hypertrophic scar (HS) is a fibroproliferative disorder resulting from abnormal healing of skin tissue after injury. Although various therapies are currently employed in clinical to treat HSs, there is no widely accepted standard therapy. Micro-plasma radiofrequency (MPR) and autologous chyle fat grafting are emerging treatments for this condition, and they have demonstrated promising therapeutic outcomes in clinical applications.
View Article and Find Full Text PDFDecellularization of human iliac artery: A vascular scaffold for peripheral repairs with human mesenchymal cells.
Tissue Cell
December 2024
National Institute of Medical Sciences and Nutrition of Mexico Salvador Zubirán (INCMNSZ), Vasco de Quiroga 15, Belisario Domínguez Secc. 16, Tlalpan, Ciudad de México 14080, Mexico.
This work presents strong evidence supporting the use of decellularized human iliac arteries combined with adipose tissue-derived stem cells (hASCs) as a promising alternative for vascular tissue engineering, opening the path to future treatments for peripheral artery disease (PAD). PAD is a progressive condition with high rates of amputation and mortality due to ischemic damage and limited graft options. Traditional synthetic grafts often fail due to poor integration, while autologous grafts may be unsuitable for patients with compromised vascular health.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!